SCHEMBL29576192

SCHEMBL29576192

CCCCOC(=O)n1ncc2cc(Oc3ccnc(Cl)n3)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.36
PLAAT3 P53816 1/20 0.36
PLAAT5 Q96KN8 1/20 0.36
PLAAT2 Q9NWW9 1/20 0.36
PLAAT4 Q9UL19 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
ASAH1 Q13510 1/20 0.35
SHMT2 P34897 2/20 0.35
RAB9A P51151 2/20 0.35
ALOX5 P09917 1/20 0.35
MEN1 O00255 1/20 0.34
PLA2G4A P47712 1/20 0.34
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
CSNK1A1 P48729 1/20 0.33
GSK3A P49840 1/20 0.33
LIMK1 P53667 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13805470 0.82 ROCK2 (0.43) KMT2AMAPTPLAAT3PLAAT5PLAAT2
SCHEMBL4782417 0.77 ATM (0.46) KMT2AALDH1A1MAPTSLC22A12ASAH1
SCHEMBL21331166 0.76 ROCK2 (0.36) KMT2AALDH1A1MAPTSLC22A12RAB9A
SCHEMBL26135772 0.74 CHEK1 (0.39) KMT2AALDH1A1MAPTSLC22A12ASAH1
SCHEMBL30786241 0.73 ASAH1 (0.57) KMT2AALDH1A1MAPTSLC22A12ASAH1
SCHEMBL9565271 0.69 ELANE (0.42) KMT2AALDH1A1MAPTRAB9AMEN1
SCHEMBL2798727 0.67 PLAAT3 (0.39) PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL4284938 0.67 KDM4C (0.43) MAPTGAA
SCHEMBL4279486 0.67 KDR (0.42)
SCHEMBL12391026 0.67 CYP2D6 (0.42) KMT2AALDH1A1MAPTRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 US disclosed
EP-4116293-A2 RHO KINASE INHIBITORS Kadmon Corporation, LLC (US) 2023-01-11 EP disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 US disclosed
EP-2903618-B1 RHO KINASE INHIBITORS KADMON CORP LLC (US) 2022-06-01 EP disclosed
US-11311541-B2 Treatment of GVHD KADMON CORPORATION, LLC (US) 2022-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 KMT2A 752/4885ALDH1A1 3146/4885MAPT 2222/4885
US-20220395501-A1 TREATMENT OF GVHD ROCK2, ROCK1, RHOXF2 KMT2A 139/4885ALDH1A1 1676/4885MAPT 4304/4885
US-11311541-B2 Treatment of GVHD ROCK2, ROCK1, RHOA KMT2A 106/4885ALDH1A1 1369/4885MAPT 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.